Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 16/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182205 | 0.79 | CTSL (0.53) | CHRM3CTSLCTSBCTSS | |
| SCHEMBL6183231 | 0.77 | CTSL (0.52) | CHRM3CTSLCTSBCTSS | |
| SCHEMBL7453120 | 0.74 | NAMPT (0.41) | — | |
| SCHEMBL6182428 | 0.73 | CTSB (0.54) | CTSLCTSBCTSS | |
| SCHEMBL7451077 | 0.73 | HDAC3 (0.45) | CHRM3 | |
| SCHEMBL6182156 | 0.73 | NAMPT (0.51) | — | |
| SCHEMBL6183502 | 0.72 | NAMPT (0.46) | — | |
| SCHEMBL6182471 | 0.72 | CTSL (0.53) | CHRM3CTSLCTSBCTSS | |
| SCHEMBL6182200 | 0.72 | CHRM3 (0.45) | CHRM3CTSBCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6183931 | 0.72 | KMT2A (0.55) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CHRM3 3393/4885CTSL 14/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.